ApoB抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Immunofluorescence analysis of HepG2 cells using ApoB mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of serun using ApoB mouse mAb (green) and negative control (purple).    

  
  

Apolipoprotein B (ApoB) is a critical structural and functional component of atherogenic lipoproteins, including low-density lipoprotein (LDL) and lipoprotein(a). It plays a central role in lipid metabolism by mediating the binding of these particles to cellular receptors, particularly the LDL receptor (LDLR). ApoB exists in two forms: ApoB-100 (full-length, synthesized in the liver) and ApoB-48 (truncated, produced in the intestine). Antibodies targeting ApoB have garnered significant interest in cardiovascular research due to their potential to modulate lipid metabolism and atherosclerosis.

Naturally occurring autoantibodies against ApoB have been identified in humans, with studies suggesting a possible protective role against cardiovascular disease by promoting the clearance of oxidized LDL or inhibiting plaque inflammation. These endogenous antibodies may influence disease progression, though their clinical significance remains under investigation.

In laboratory settings, monoclonal and polyclonal ApoB antibodies are widely used as research tools to quantify ApoB-containing lipoproteins, study their metabolism, and assess cardiovascular risk. Therapeutic applications are also being explored, including ApoB-targeted vaccines and antibody-based therapies designed to neutralize atherogenic particles or enhance their clearance. Notably, some experimental antibodies aim to block ApoB's interaction with proteoglycans in arterial walls, a key step in plaque formation. However, challenges persist in developing clinically viable ApoB antibodies, balancing efficacy with safety concerns related to potential off-target effects. Current research continues to unravel the complex roles of ApoB immunity in both pathological and protective contexts.